Memorial Sloan Kettering Cancer Center

FDA approved lazertinib plus amivantamab for EGFR-mutant NSCLC, offering a third first-line option alongside osimertinib. MARIPOSA trial showed the combination reduced progression risk by 30% with median PFS of 23.7 months. Clinicians vary in choice, balancing benefits and side effects, with ongoing efforts to mitigate adverse events.

The AACR Molecular Biology in Clinical Oncology Workshop, directed by Ross L. Levine, with codirectors Christine M. Lovly and Jean Y. Tang, aims to train aspiring physician-scientists in molecular biology, translational cancer research, and grant writing. Held July 20-26, 2025, at Loews Coronado Bay Resort, the workshop includes lectures, lab sessions, mentoring, and networking opportunities. Previous attendees highlight its impact on their careers.

Research on gut microbiome's role in cancer care has advanced rapidly, revealing its impact on prognosis and immunotherapy response. Key findings include the identification of beneficial bacteria like *Akkermansia muciniphila* and detrimental effects of antibiotics on survival. New technologies, such as PCR chips and oral charcoal capsules, aim to mitigate antibiotic-induced dysbiosis and enhance immunotherapy efficacy. Fecal microbiota transplantation (FMT) shows promise in overcoming immunotherapy resistance, while dietary interventions, such as increased fiber intake, also influence outcomes. Future cancer care may include routine microbiome analysis to tailor treatments.

Break Through Cancer launches phase 2 trial using revumenib and venetoclax to eliminate minimal residual disease in acute myeloid leukemia, aiming to prevent relapse and improve survival rates.

Phase 1 trial data shows selinexor plus ruxolitinib nearly doubles SVR35 to 79% in myelofibrosis patients, with significant Abs-TSS improvements, supporting Phase 3 SENTRY trial.

Itovebi-based combination therapy more than doubled progression-free survival in advanced breast cancer patients, reducing disease risk by 57%, and was recently approved by the US FDA for HR-positive, HER2-negative breast cancer with a PIK3CA mutation.

Roche announced phase III INAVO120 trial results for Itovebi in NEJM, showing 57% reduction in HR-positive, HER2-negative breast cancer progression or death risk with median progression-free survival of 15.0 months vs. 7.3 months. FDA approved Itovebi as first-line treatment for PIK3CA-mutated cases.

Itovebi-based regimen reduces disease worsening or death risk by 57% in HR-positive, HER2-negative breast cancer with PIK3CA mutation, per INAVO120 study. FDA approved Itovebi as first-line treatment, with data published in the New England Journal of Medicine.